News from aragon pharmaceuticals

Oct 04, 2012, 08:00 ET
Aragon Pharmaceuticals is focused on the development of second generation anti-hormonal agents for hormone-driven cancers. The company's portfolio of small molecule therapeutics is based upon pioneering research identifying key molecular events that lead to drug resistance to traditional anti-hormonal therapies. This work has broad implications for the development of breakthrough medicines for prostate cancer and other hormone-dependent cancers. Aragon Pharmaceuticals' most advanced compound, ARN-509, is an androgen receptor antagonist that is currently being evaluated in a Phase 2 trial in patients with castration-resistant prostate cancer. Aragon is a private company founded in 2009.  (PRNewsFoto/Aragon Pharmaceuticals)
Oct 01, 2012, 08:00 ET
Aug 28, 2012, 08:00 ET
Aragon Pharmaceuticals is focused on the development of second generation anti-hormonal agents for hormone-driven cancers. The company's portfolio of small molecule therapeutics is based upon pioneering research identifying key molecular events that lead to drug resistance to traditional anti-hormonal therapies. This work has broad implications for the development of breakthrough medicines for prostate cancer and other hormone-dependent cancers. Aragon Pharmaceuticals' most advanced compound, ARN-509, is an androgen receptor antagonist that is currently being evaluated in a Phase 2 trial in patients with castration-resistant prostate cancer. Aragon is a private company founded in 2009.  (PRNewsFoto/Aragon Pharmaceuticals)
Mar 06, 2012, 07:00 ET
Aug 02, 2010, 08:00 ET
May 20, 2009, 10:30 ET

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer